Quality CareFind out why Mayo Clinic is the right place for your health care. Make an appointment.
Meet the StaffFind a directory of doctors and departments at all Mayo Clinic campuses. Visit now.
Research and Clinical TrialsSee how Mayo Clinic research and clinical trials advance the science of medicine and improve patient care. Explore now.
Visit Our SchoolsEducators at Mayo Clinic train tomorrow’s leaders to deliver compassionate, high-value, safe patient care. Choose a degree.
Professional ServicesExplore Mayo Clinic's many resources and see jobs available for medical professionals. Get updates.
Philanthropy at Mayo ClinicYour support accelerates powerful innovations in patient care, research and education. Give today.
Search Results 1-10 of 33 for Huntington's+disease
A Dose-response of the Effects of Exendin-9,39 on GI Symptoms and Food Intake - Mayo Clinic Overview Tab Title Description Study type Interventional Study IDs Study type Interventional Describes the nature of a clinical study.
Study to Determine Effect of Exendin-9,39 Infusion on Insulin Secretion - Mayo Clinic Overview Tab Title Description Study type Observational Study IDs Study type Observational Describes the nature of a clinical study.
A Study of the Effects of Exendin-9,39 on Glucose Metabolism, Glucagon and Insulin Secretion, and on Insulin Action - Mayo Clinic Overview Tab Title Description Study type Interventional Study phase I Study IDs Study type Interventio...
Randomized, Placebo Controlled Study Of The Efficacy And Safety Of PF-02545920 In Subjects With Huntington's Disease - Mayo Clinic Overview Tab Title Description Study type Interventional Study phase II Study IDs Stu...
A Study to Investigate the Long Term Safety, Tolerability And Effectiveness of Pf-02545920 in Subjects with Huntington's Disease Who Completed Study A8241021 - Mayo Clinic Overview Tab Title Description Study type In...
Patients fulfilled NINCDS-ADRDA criteria and were genotyped for APOE epsilon4 (15 epsilon4/epsilon4, 39 epsilon4/- and 29-/-).
Increased blood volume was associated with increased pulmonary capillary wedge pressure (p = 0.01) and greatly increased risk of death or urgent cardiac transplantation during a median follow-up of 719 days (1-year event rate 39% vs ...
The 2-year progression-free survival and overall survival, were 39% (95% confidence interval 21-57) and 60% (95% confidence interval 39-76), respectively.
Median overall survival for this group of 39 patients was 35 weeks.
The group of CYSF were significantly younger (39 vs. 54 years) and suffered longer from kidney stones (255 vs. 136 months).
Mayo Clinic does not endorse companies or products. Advertising revenue supports our not-for-profit mission.
Check out these best-sellers and special offers on books and newsletters from Mayo Clinic.
Mayo Clinic is a nonprofit organization and proceeds from Web advertising help support our mission. Mayo Clinic does not endorse any of the third party products and services advertised.
A single copy of these materials may be reprinted for noncommercial personal use only. "Mayo," "Mayo Clinic," "MayoClinic.org," "Mayo Clinic Healthy Living," and the triple-shield Mayo Clinic logo are trademarks of Mayo Foundation for Medical Education and Research.